Johnson & Johnson $JNJ Stock Sold by PineStone Asset Management Inc.

Key Points

• PineStone Asset Management reduced its Johnson & Johnson stake by 5.6%, selling 97,100 shares and retaining 1.64 million shares valued at approximately $433.3 million. J&J remains about 2.9% of PineStone’s portfolio.
• Johnson & Johnson reported third-quarter revenue of $25.4 billion and adjusted EPS of $2.59, both slightly above expectations, while raising its 2026 operational sales outlook to roughly $100.7 billion at the midpoint.
• The company maintained its quarterly dividend at $1.34 per share, but MedTech sales weakness, premium valuation, and recent insider selling remain potential concerns despite continued institutional ownership and a generally positive analyst view.

PineStone Asset Management Inc. lowered its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 5.6% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,636,744 shares of the company's stock after selling 97,100 shares during the period. Johnson & Johnson makes up approximately 2.9% of PineStone Asset Management Inc.'s portfolio, making the stock its 14th biggest holding. PineStone Asset Management Inc. owned about 0.07% of Johnson & Johnson worth $433,312,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in JNJ. Auto Owners Insurance Co raised its position in Johnson & Johnson by 22,225.6% in the fourth quarter. Auto Owners Insurance Co now owns 69,419,308 shares of the company's stock worth $1,436,633,000 after acquiring an additional 69,108,368 shares in the last quarter. Jupiter Topco LLC acquired a new position in Johnson & Johnson in the 2nd quarter valued at about $1,967,399,000. Diamant Asset Management Inc. grew its holdings in shares of Johnson & Johnson by 24,436.5% during the first quarter. Diamant Asset Management Inc. now owns 4,473,008 shares of the company's stock worth $109,338,000 after buying an additional 4,454,778 shares in the last quarter. Corient Private Wealth LP raised its position in shares of Johnson & Johnson by 127.3% in the second quarter. Corient Private Wealth LP now owns 6,060,922 shares of the company's stock valued at $1,539,292,000 after buying an additional 3,393,981 shares during the last quarter. Finally, Wellington Management Group LLP lifted its stake in shares of Johnson & Johnson by 12.5% during the second quarter. Wellington Management Group LLP now owns 22,588,696 shares of the company's stock valued at $5,736,851,000 after buying an additional 2,513,321 shares during the period. Institutional investors and hedge funds own 69.55% of the company's stock.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Raised 2026 outlook: Third-quarter operational sales grew 6%, reaching $25.4 billion, and management increased full-year operational sales guidance to approximately $100.7 billion at the midpoint. Adjusted EPS also exceeded analysts’ expectations. Johnson & Johnson: 3 Key Takeaways for Long-Term Investors
• Positive Sentiment: Pharmaceutical momentum and pipeline potential: Strong demand for TREMFYA, early momentum for ICOTYDE and oncology investments helped offset weakness elsewhere. Investors are also watching J&J’s newly approved surgical robot as a potential long-term MedTech growth driver. Does Raised 2026 Outlook Change the Bull Case for Johnson & Johnson?
• Positive Sentiment: Defensive appeal and income support: Investors rotating away from technology stocks amid inflation and interest-rate concerns are favoring dividend-paying healthcare companies. J&J also affirmed its $1.34-per-share fourth-quarter dividend, payable in December 2026. Morgan Stanley maintained an “overweight” rating with a $292 price target.
• Neutral Sentiment: Institutional demand: ETFs recorded approximately $107.4 million of net buying in JNJ, suggesting some portfolio managers continue to view the company as a defensive holding. However, this flow is not necessarily evidence of a change in operating fundamentals. Johnson & Johnson Sees $107.4 Million in Net ETF Buying
• Negative Sentiment: MedTech weakness remains the main overhang: Medical-device sales missed Wall Street forecasts, while international pricing pressure and acquisition-related costs weighed on results. Analysts described the quarter as setting a negative tone for the broader pharmaceutical sector. Johnson & Johnson Stock Falls on MedTech Miss
• Negative Sentiment: Valuation and analyst caution: JNJ trades at a premium earnings multiple, increasing the risk of further pressure if growth disappoints. Erste Group expressed a negative view on fiscal 2027 earnings, while RBC lowered its price expectations.

Johnson & Johnson Trading Down 0.0%

Shares of NYSE JNJ opened at $255.54 on Monday. The company has a market cap of $615.82 billion, a price-to-earnings ratio of 38.72, a price-to-earnings-growth ratio of 2.53 and a beta of 0.21. The stock's 50 day simple moving average is $265.66 and its 200 day simple moving average is $249.66. Johnson & Johnson has a 12-month low of $184.66 and a 12-month high of $281.07. The company has a current ratio of 1.09, a quick ratio of 0.81 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, beating the consensus estimate of $2.53 by $0.06. The firm had revenue of $25.40 billion for the quarter, compared to the consensus estimate of $25.38 billion. Johnson & Johnson had a return on equity of 31.54% and a net margin of 16.20%. The firm's revenue for the quarter was up 5.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.80 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Equities research analysts expect that Johnson & Johnson will post 11.12 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be issued a $1.34 dividend. The ex-dividend date of this dividend is Tuesday, November 24th. This represents a $5.36 annualized dividend and a dividend yield of 2.1%. Johnson & Johnson's dividend payout ratio is currently 81.21%.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Elizabeth Forminard sold 15,918 shares of the firm's stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $257.00, for a total value of $4,090,926.00. Following the completion of the transaction, the executive vice president directly owned 16,994 shares in the company, valued at $4,367,458. This trade represents a 48.37% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Jennifer L. Taubert sold 15,000 shares of the stock in a transaction on Monday, August 17th. The shares were sold at an average price of $263.36, for a total value of $3,950,400.00. Following the completion of the sale, the executive vice president owned 194,451 shares of the company's stock, valued at $51,210,615.36. The trade was a 7.16% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 64,515 shares of company stock valued at $17,271,766 in the last three months. 0.16% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on JNJ. HSBC increased their price objective on shares of Johnson & Johnson from $290.00 to $320.00 and gave the stock a "buy" rating in a report on Thursday, September 10th. UBS Group set a $270.00 target price on shares of Johnson & Johnson in a research report on Wednesday. Weiss Ratings raised shares of Johnson & Johnson from a "buy (b)" rating to a "buy (b+)" rating in a research report on Thursday, October 8th. JPMorgan Chase & Co. raised their price objective on Johnson & Johnson from $270.00 to $285.00 and gave the company a "neutral" rating in a research report on Tuesday, September 29th. Finally, Johnson Rice restated a "buy" rating on shares of Johnson & Johnson in a report on Monday, August 3rd. One research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have given a Hold rating to the company's stock. According to data from MarketBeat, Johnson & Johnson has an average rating of "Moderate Buy" and an average price target of $274.87.

Johnson & Johnson Company Profile

Johnson & Johnson NYSE: JNJ is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.